UM

Browse/Search Results:  1-4 of 4 Help

Selected(0)Clear Items/Page:    Sort:
TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance Journal article
Acta Pharmacologica Sinica, 2020,Volume: 42,Issue: 3,Page: 451-459
Authors:  Jiang,Xiao ming;  Xu,Yu lian;  Yuan,Luo wei;  Zhang,Le le;  Huang,Mu yang;  Ye,Zi han;  Su,Min xia;  Chen,Xiu ping;  Zhu,Hong;  Ye,Richard D.;  Lu,Jin jian
Favorite |  | TC[WOS]:4 TC[Scopus]:4 | Submit date:2021/03/01
Egfr Mutant Non-small Cell Lung Cancer  Epithelial-mesenchymal Transition  Nf-κb  Osimertinib Resistance  Tgfβ2  
Increased expression of IRE1α associates with the resistant mechanism of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells Journal article
Anti-Cancer Agents in Medicinal Chemistry, 2018,Volume: 18,Issue: 4,Page: 550-555
Authors:  Tang Z.-H.;  Su M.-X.;  Guo X.;  Jiang X.-M.;  Jia L.;  Chen X.;  Lu J.-J.
Favorite |  | TC[WOS]:7 TC[Scopus]:10 | Submit date:2018/12/28
Azd9291  Egfr  Ire1α  Lune Cancer  Nsclc  Osimertinib  
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies Journal article
CANCER LETTERS, 2018,Volume: 420,Page: 242-246
Authors:  Tang, Zheng-Hai;  Lu, Jin-Jian
Favorite |  | TC[WOS]:57 TC[Scopus]:58 | Submit date:2018/10/30
Osimertinib  Azd9291  Egfr Tki  Resistant Mechanisms  Therapeutic Strategies  
Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line Journal article
Oncotarget, 2016,Volume: 7,Issue: 49,Page: 81598-81610
Authors:  Tang Z.-H.;  Jiang X.-M.;  Guo X.;  Fong C.M.V.;  Chen X.;  Lu J.-J.
Favorite |  | TC[WOS]:30 TC[Scopus]:30 | Submit date:2018/12/28
Azd9291  Egfr  Navitoclax  Nsclc  Osimertinib